Simulating the cost-effectiveness of lung cancer screening by low-dose CT scan in Canada.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6550-6550
Author(s):  
John R. Goffin ◽  
William M Flanagan ◽  
Anthony Miller ◽  
Fei Fei Liu ◽  
Sonya Cressman ◽  
...  

6550 Background: The National Lung Screening Trial (NLST) demonstrated that low-dose CT screening diminishes the risk of death among smokers. A cost-effectiveness analysis was undertaken in the context of the Canadian publically funded healthcare system. Methods: Microsimulation of CT screening was undertaken using the Cancer Risk Management Model, which incorporates demographic data, cancer risk factors, cancer registry data, diagnostic and treatment algorithms and health utilities. Simulations were performed at the individual level for a cohort incepted during the period 2012-2032. The criteria for the screen-eligible population, CT scan test characteristics, and screened cohort outcomes were derived from NLST and Canadian data. The baseline screening scenario was annual CT screening for ≥30 pack-year smokers, age 55 to 74. Simulation assumed 60% of the eligible population participates by 10 years, 70% adhere to the screening regimen, and smoking cessation rates are unchanged. One-way sensitivity analyses were performed. Costs and life-years lived were discounted at 3% annually. Results: Compared to no screening, annual screening results in incremental system costs of $2.97 billion (Cdn), 149,000 life-years saved (LYS) or 55,000 quality-adjusted life-years saved (QALYS), an incremental cost-effectiveness ratio (ICER) of $19,900/LYS, and $53,700/QALYS. With participation rates from 40% to 80%, ICER /QALYS remained within the range of $53,700 to $58,200. Increases in screening adherence from 50% through 90% increased the ICER /QALY from $50,400 to $58,800. Higher rates of smoking cessation led to improvements in ICER /QALY (150% of background cessation rate of 3.2-5.3%, $47,000; 200%, $41,500; 300%, $32,900). A system of biennial screening had a net cost of $1.81 billion, resulting in an ICER of $19,600 /LYS, and $54,800 /QALYS. Conclusions: Screening for lung cancer with low-dose CT scans could be cost-effective, but requires substantial system costs. The smoking cessation rate greatly impacts the ICER and a cessation program should be considered if screening is implemented. Compared to annual screening, biennial screening costs less and produces a similar ICER. Further analyses will be detailed.

CHEST Journal ◽  
2003 ◽  
Vol 124 (2) ◽  
pp. 614-621 ◽  
Author(s):  
Juan P. Wisnivesky ◽  
Alvin I. Mushlin ◽  
Nachum Sicherman ◽  
Claudia Henschke

Lung Cancer ◽  
2018 ◽  
Vol 121 ◽  
pp. 61-69 ◽  
Author(s):  
Yuki Tomonaga ◽  
Kevin ten Haaf ◽  
Thomas Frauenfelder ◽  
Malcolm Kohler ◽  
Roger D. Kouyos ◽  
...  

Lung Cancer ◽  
2018 ◽  
Vol 126 ◽  
pp. 119-124 ◽  
Author(s):  
Sebastian Hinde ◽  
Tessa Crilly ◽  
Haval Balata ◽  
Rachel Bartlett ◽  
John Crilly ◽  
...  

Author(s):  
Christopher J Cadham ◽  
Pianpian Cao ◽  
Jinani Jayasekera ◽  
Kathryn L Taylor ◽  
David T Levy ◽  
...  

Abstract Background Guidelines recommend offering cessation interventions to smokers eligible for lung cancer screening, but there is little data comparing specific cessation approaches in this setting. We compared the benefits and costs of different smoking cessation interventions to help screening programs select specific cessation approaches. Methods We conducted a societal-perspective cost-effectiveness analysis using a Cancer Intervention and Surveillance Modeling Network model simulating individuals born in 1960 over their lifetimes. Model inputs were derived from Medicare, national cancer registries, published studies, and micro-costing of cessation interventions. We modeled annual lung cancer screening following 2014 US Preventive Services Task Force guidelines plus cessation interventions offered to current smokers at first screen, including pharmacotherapy only or pharmacotherapy with electronic and/or web-based, telephone, individual, or group counseling. Outcomes included lung cancer cases and deaths, life-years saved, quality-adjusted life-years (QALYs) saved, costs, and incremental cost-effectiveness ratios. Results Compared with screening alone, all cessation interventions decreased cases of and deaths from lung cancer. Compared incrementally, efficient cessation strategies included pharmacotherapy with either web-based cessation ($555 per QALY), telephone counseling ($7562 per QALY), or individual counseling ($35 531 per QALY). Cessation interventions continued to have costs per QALY well below accepted willingness to pay thresholds even with the lowest intervention effects and was more cost-effective in cohorts with higher smoking prevalence. Conclusion All smoking cessation interventions delivered with lung cancer screening are likely to provide benefits at reasonable costs. Because the differences between approaches were small, the choice of intervention should be guided by practical concerns such as staff training and availability.


2020 ◽  
Vol 109 (3) ◽  
pp. 611-616
Author(s):  
Yuichi Takiguchi

2012 ◽  
Vol 198 (3) ◽  
pp. 505-511 ◽  
Author(s):  
Peter C. Jacobs ◽  
Martijn J. A. Gondrie ◽  
Yolanda van der Graaf ◽  
Harry J. de Koning ◽  
Ivana Isgum ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document